BioSpace News Archive

iVeena Delivery Systems Inc. is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.

Triveni Bio Inc. announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.

Mallinckrodt plc, a global specialty pharmaceutical company, recently shared findings from Mallinckrodt’s latest health economics outcomes research on Acthar® Gel for patients with advanced symptomatic sarcoidosis and nephrotic syndrome 1,2 at the Academy of Managed Care Pharmacy Nexus 2023 in Orlando, FL October 16-19, 2023.

Chimerix announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2023, and updated full-year guidance.

Vivos Therapeutics, Inc. announced that it will effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”), effective with the opening of trading on Friday, October 27, 2023.

Mind Medicine (MindMed) Inc. announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended September 30, 2023.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Cybin Inc. today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.